Navigation Links
Prematics CEO Joins Initiative to Advance More Coordinated, Connected Health Care
Date:5/27/2008

TransforMED Names Kevin Hutchinson to Inaugural Board of Managers

BETHESDA, Md., May 27 /PRNewswire/ -- Prematics president and chief executive officer, Kevin Hutchinson, has been named an inaugural member of the Board of Managers for TransforMED LLC, a wholly owned subsidiary of the American Academy of Family Physicians (AAFP). TransforMED will provide support and consulting services to primary care physicians and health systems that want to transform their medical practices into patient-centered medical homes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060623/PREMATICSLOGO )

The TransforMED medical home model combines the relationship-centered values of family medicine with new technologies to improve care quality, efficiency and patient and physician satisfaction. As patient-centered medical homes, primary care practices serve as the focal point of care coordination across all specialties for patients, maintaining central and complete patient records. The model also calls for adoption of information technologies as an essential component to improving diagnostic capabilities and enhancing treatment and outcomes.

"The complex challenges facing today's health care system are forcing physician practices and motivating patients to rethink the way care is delivered," said Mr. Hutchinson. "I'm pleased to be a member of the TransforMED board as it provides critical tools and support for practices navigating the transformation to a patient-centered medical home and implementing new technologies for more coordinated, patient-centered care."

Mr. Hutchinson leads Prematics, a company assisting practices with the move to more connected, efficient care through the exchange of clinical transactions and patient information using standards-based and proven technologies, starting with electronic prescribing. The company's medication management service
'/>"/>

SOURCE Prematics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Availity Engages Prematics to Deploy Electronic Prescribing Solution
2. Availity Engages Prematics to Deploy Electronic Prescribing
3. Accenx Technologies Joins Suns Authorized Subcontractor Program
4. C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland
5. Col. Robert E. Shields Joins Palmetto GBAs Board of Directors
6. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
7. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
8. Lisa M. Suennen Joins OmniGuide(R) Board of Directors
9. William M. Wagner Joins NHP as Vice President and Controller
10. Simuality Joins Efforts for Myanmar Relief
11. Booth Joins PrePak Systems for Growth, Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...effective against Lennox-Gastaut syndrome , ...ug called Banzel (rufinamide) has been approved as...ilepsy called Lennox-Gastaut syndrome, the U.S. Fo...The approval was based on results of a four-month .... Compared to patients who took a placebo, those w...
(Date:11/21/2008)...PRNewswire-USNewswire/ -- New research at West Vi...s, spitless tobacco product aimed at young adults ...t RJ Reynolds, Camel Snus - touted as a socially a...risingly high levels of nicotine. , , "Came...f products," said Bruce Adkins of the state Divisi...
(Date:11/21/2008)...ewswire-USNewswire/ -- U.S. News & World Repor... (NCQA) ranked BlueChoice(R) HealthPlan of South C...Plans(TM), published in U.S. News & World Repo...ual ranking ranks the nation,s best health plans b...NCQA accreditation scores. NCQA and U.S. News &...
(Date:11/21/2008)...ewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (...s overwhelmingly approved the proposals submitted ...a Pharmaceuticals Industries Ltd. (Nasdaq: TEVA ...whelming support of the transaction by the Barr sh... and CEO. "We are pleased with the progress that w...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...rganization (NACO) of India plans to promote the d...attle against HIV/AIDS//. The third phase of the N...y to be launched in April. Statistics show that ...the private sector for outpatient care and over 50...
...fusal of surgery to known smokers is all set to be...ating the issue in this week’s BMJ//. The issue wa...t last year to remove smokers from the waiting lis...Peters who is from Concord Repatriation General Ho...
...on therapy on the exterior along with radiation se...highly effective// for treatment of prostate cance...of Radiation Oncology Biology Physics has revealed...undergone such a combination therapy have been com...
...or Disease Control and Prevention (CDC) Atlanta's ...is time the US changed its guidelines// and made T...irrespective of how long they have been residing t...ated if all foreign-born residents from high-risk ...
Other Medicine News:Health News:Refusal of Surgery for Smokers – To Be or Not to Be 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2
(Date:11/21/2008)...England, November 21 , ...an Committee for Medicinal Products for Human Use ...n for the approval of Enbrel(R),(etanercept) as a...,adolescents with severe plaque psoriasis. If appr...mmittee,s recommendation, Enbrel will become the,...
(Date:11/20/2008)... , , PHILADELPHIA, Nov. 20 /PRNewswire-Firs...unced that the United States Food and Drug Adminis...MACTA(R) (eltrombopag) for the treatment of thromb...thic) thrombocytopenic purpura (ITP) who have had ...oglobulins or splenectomy. The approval is a signi...
(Date:11/20/2008)...lif., Nov. 20 Duska Ther...nced today that it has submitted its,pivotal Phas...r a Special,Protocol Assessment (SPA) procedure w..., Subject to securing an agreement with the...tive, double-blind, placebo-controlled and randomi...
(Date:11/19/2008)...O, Nov. 19 Posit Science Corporati...the Society for Neuroscience,Annual Conference in...e,training may benefit Baby Boomers. The compute...m (TM) uses adaptive exercises that target auditor...ed to drive generalized,improvements in cognition...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pregnant mice block out unwelcome admirers to protect their pups 4122 1Pregnant mice block out unwelcome admirers to protect their pups 4122 2Capella University Launches Online PhD Specialization in Nursing Education 24214 1Capella University Launches Online PhD Specialization in Nursing Education 24214 2Capella University Launches Online PhD Specialization in Nursing Education 24214 3Incidence of Mantle Cell Lymphoma on Rise 24211 1Incidence of Mantle Cell Lymphoma on Rise 24211 2Breast Fed Babies Have Fewer GI Infections 24208 1Breast Fed Babies Have Fewer GI Infections 24208 2
...roach to Address Growing Problem of Antibiotic Res...ER, British Columbia, March 26, 2007 /PRNewswire/ ... IDR-1 is the first,immune system trigger to cure ...ccording to a paper published in the April 2007,is...ghlights the work of Inimex and its,co-founders Dr...
...rial Shows CRESTOR Slowed Progression Of Atheroscl...sease , LONDON, March 26, 2006-AstraZeneca today a... is the first study to show a,positive effect on a...id artery disease and at low risk of coronary hear...uvastatin) 40mg and presented at,56th Scientific S...
Other Medicine Technology:Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 3First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 4First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 5
Grafton DBM Matrix PLF is the first bone graft material designed specifically for posterolateral fusion procedures. Unique trough-like design allows for easy use with allograft/autograft bone. Demine
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%.
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%.
Inductive demineralized bone matrix and conductive cancellous chips. DBM and cancellous chips will be free of foreign matter. Demineralized bone matrix particle size is 125 to 1000 . Cancellous chip
Medicine Products: